

5774-01-AWZ (PC17354)
Application No. 09/674,819

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

RECEIVED
CENTRAL FAX CENTER
SEP 12 2006

Listing of Claims:

Claims 1-27 (cancelled).

Claim 28 (currently amended): A stabilized solid composition comprising a 4-amino-3-substituted butanoic acid derivative and ~~a humectant~~ propylene glycol, wherein the 4-amino-3-substituted butanoic acid derivative is gabapentin or pregabalin, or a combination thereof, ~~and the humectant is propylene glycol.~~

Claims 29-34 (cancelled).

Claim 35 (currently amended): The stabilized solid composition of claim 28, wherein the amount of the ~~humectant~~ propylene glycol is 0.01-25 % by weight relative to the 4-amino-3-substituted butanoic acid derivative.

Claim 36 (previously presented): The stabilized solid composition of claim 28, further comprising an auxiliary agent.

Claim 37 (currently amended): The stabilized solid composition of claim 36, wherein the total amount of the ~~humectant~~ propylene glycol is 0.01-25 % by weight relative to the 4-amino-3-substituted butanoic acid derivative and the auxiliary agent.

Claims 38-39 (cancelled).

Claim 40 (previously presented): The stabilized solid composition of claim 28, wherein the stabilized solid composition is a pharmaceutical preparation in the form of tablets, granules or capsules.

5774-01-AWZ (PC17354)
Application No. 09/674,819

Claim 41 (currently amended): A process for stabilizing a solid composition containing a 4-amino-3-substituted butanoic acid derivative, the process comprising combining the 4-amino-3-substituted butanoic acid derivative with ~~humectant~~ propylene glycol, wherein the 4-amino-3-substituted butanoic acid derivative is gabapentin or pregabalin, or a combination thereof, ~~and the humectant is propylene glycol.~~

Claim 42 (cancelled).

Claim 43 (new): The stabilized solid composition of claim 28, wherein after storage of the composition in a sealed container at 60°C for 2 weeks the content of the corresponding lactam that is formed in the composition is less than 0.20% by weight relative to the initial amount of the 4-amino-3-substituted-butanoic acid derivative in the composition.